2013
DOI: 10.1016/j.ijcard.2013.06.045
|View full text |Cite
|
Sign up to set email alerts
|

Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis

Abstract: In this study, i.v. iron substitution, exercise tolerance, stroke, country of residence and renal function influenced measures of HRQoL in patients with heart failure and iron deficiency.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
15
0
4

Year Published

2015
2015
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 33 publications
(20 citation statements)
references
References 27 publications
1
15
0
4
Order By: Relevance
“…In HF patients, anaemia is probably a marker of: 1) accumulation of factors which are themselves important predictors of unfavourable outcomes in HF (such as older age, malnutrition, frailty, and higher non-cardiac co-morbidity burden, including chronic kidney disease), both by their direct influence and due to our tendency to under-prescribe evidence-based HF therapies in such patients, 2) iron deficiency, which might itself aggravate skeletal and heart muscle dysfunction, and 3) more advanced HF stages because anaemia in severe HF might result from subclinical inflammation (anaemia of chronic disorders) as well as from haemodilution in patients with fluid retention [31,32]. These assumptions are supported by the fact that iron supplementation (in both anaemic and non-anaemic HF patients), but not darbepoetin or erythropoietin treatment, has led to an improvement in functional capacity and a reduction in hospitalisations for symptom deterioration in HF [33][34][35]. The four presented models were chosen because they were derived from the largest cohorts.…”
Section: Genetic Testingmentioning
confidence: 99%
“…In HF patients, anaemia is probably a marker of: 1) accumulation of factors which are themselves important predictors of unfavourable outcomes in HF (such as older age, malnutrition, frailty, and higher non-cardiac co-morbidity burden, including chronic kidney disease), both by their direct influence and due to our tendency to under-prescribe evidence-based HF therapies in such patients, 2) iron deficiency, which might itself aggravate skeletal and heart muscle dysfunction, and 3) more advanced HF stages because anaemia in severe HF might result from subclinical inflammation (anaemia of chronic disorders) as well as from haemodilution in patients with fluid retention [31,32]. These assumptions are supported by the fact that iron supplementation (in both anaemic and non-anaemic HF patients), but not darbepoetin or erythropoietin treatment, has led to an improvement in functional capacity and a reduction in hospitalisations for symptom deterioration in HF [33][34][35]. The four presented models were chosen because they were derived from the largest cohorts.…”
Section: Genetic Testingmentioning
confidence: 99%
“…3) [1,13,14] Agata Tymińska i wsp., Niedokrwistość i niedobór żelaza w niewydolności serca badaniach potwierdzono związek przyczynowy między niedoborem żelaza (z niedokrwistością i bez niedokrwistości) a wpływem na tolerancję wysiłku i jakość życia pacjentów z HF [33][34][35]. Ponadto Klip i wsp.…”
Section: Rokowanieunclassified
“…Jednak, jak do tej pory, w żadnym z badań nie wykazano przekonujących wyników dotyczących poprawy przeżywalności pacjentów z niedokrwistością i towarzyszącą HF [1,[33][34][35], natomiast istnieją dowody na korzyści ze stosowania terapii żelazem w kontekście poprawy objawów i jakości życia u pacjentów z niedoborem żelaza, niezależnie od występowania niedokrwistości [1,[33][34][35].…”
Section: Leczenieunclassified
See 2 more Smart Citations